SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Dalianis Tina) "

Sökning: WFRF:(Dalianis Tina)

  • Resultat 1-10 av 39
  • [1]234Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Dalianis, Tina, et al. (författare)
  • Management of BK-virus infection - Swedish recommendations.
  • 2019
  • Ingår i: Infectious diseases (London, England). - 2374-4243. ; 51:7, s. 479-484
  • Tidskriftsartikel (refereegranskat)abstract
    • BK-virus (BKV) associated nephropathy (BKVAN) and BKV associated haemorrhagic cystitis (HC) are complications of BKV infection/reactivation in renal and allogeneic haematopoietic stem cell transplantation (HSCT) patients, respectively. The task of how to manage these diseases was given to the chair by the Swedish Reference Group for Antiviral Therapy (RAV). After individual contributions by members of the working group, consensus discussions were held in a meeting on 23 January 2018 arranged by RAV. Thereafter, the recommendations were published in Swedish on November 2018. The current translation to English has been approved by all co-authors. High BKV serum levels suggest an increased risk for BKVAN and potential graft failure. For detection of BKVAN, careful monitoring of BKV DNA levels in serum or plasma is recommended the first year after renal transplantation and when increased creatinine serum levels of unknown cause are observed. Notably, a renal biopsy is mandatory for diagnosis. To reduce the risk for progression of BKVAN, there is no specific treatment, and tailored individual decrease of immunosuppression is recommended. For BKV-HC, BKV monitoring is not recommended, since BK-viruria frequently occurs in HSCT patients and the predictive value of BKV in plasma/serum has not been determined. However, the risk for BKV-HC is higher for patients undergoing myeloablative conditioning, having an unrelated, HLA-mismatched, or a cord blood donor, and awareness of the increased risk and early intervention may benefit the patients. Also for BKV-HC, no specific therapy is available. Symptomatic treatment, e.g. forced diuresis and analgesics could be of use.
  •  
2.
  •  
3.
  • Söderström, Karin, et al. (författare)
  • Regional recurrence of oropharyngeal cancer after definitive radiotherapy: a case control study.
  • 2015
  • Ingår i: Radiation Oncology. - BioMed Central (BMC). - 1748-717X. ; 10:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Elective treatment of lymph nodes in oropharyngeal cancer (OPC) has impact on both regional recurrences (RR) and risk of late side effects. This study was performed to quantify the dose-dependent impact on RR and overall survival (OS) in a prospectively collected cohort of OPC from the ARTSCAN study with emphasis on elective treatment.
4.
  •  
5.
  • Bersani, Cinzia, et al. (författare)
  • A model using concomitant markers for predicting outcome in human papillomavirus positive oropharyngeal cancer
  • 2017
  • Ingår i: Oral Oncology. - Elsevier. - 1368-8375 .- 1879-0593. ; 68, s. 53-59
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Objective: Head-neck cancer therapy has become intensified. With radiotherapy alone, 3-year disease-free survival (DFS) is 80% for HPV-positive TSCC/BOTSCC and better for patients with favorable characteristics, suggesting therapy could be tapered for some, decreasing side-effects. Therefore, we built a model to predict progression-free survival for patients with HPV-positive TSCC and BOTSCC. Material and methods: TSCC/BOTSCC patients treated curatively between 2000 and 2011, with HPV16 DNA/E7 mRNA positive tumors examined for CD8(+) TILs, HPV16 mRNA and HLA class I expression were included. Patients were split randomly 65/35 into training and validation sets, and LASSO regression was used to select a model in the training set, the performance of which was evaluated in the validation set. Results: 258 patients with HPV DNA/E7 mRNA positive tumors could be included, 168 and 90 patients in the respective sets. No treatment improved prognosis compared to radiotherapy alone. CD8(+) TIL counts and young age were the strongest predictors of survival, followed by T-stage &lt;3 and presence of HPV16 E2 mRNA. The model had an area under curve (AUC) of 76%. A model where the presence of three of four of these markers defined good prognosis captured 56% of non-relapsing patients with a positive predictive value of 98% in the validation set. Furthermore, the model identified 35% of our cohort that was over-treated and could safely have received de-escalated therapy. Conclusion: CD8(+) TIL counts, age, T-stage and E2 expression could predict progression-free survival, identifying patients eligible for randomized trials with milder treatment, potentially reducing side effects without worsening prognosis.</p>
  •  
6.
  • Bersani, Cinzia, et al. (författare)
  • MicroRNA-155,-185 and-193b as biomarkers in human papillomavirus positive and negative tonsillar and base of tongue squamous cell carcinoma
  • 2018
  • Ingår i: Oral Oncology. - Elsevier. - 1368-8375 .- 1879-0593. ; 82, s. 8-16
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Objective: Three-year disease-free survival (DFS) is 80% for human papillomavirus (HPV) positive tonsillar and base of tongue cancer (TSCC/BOTSCC) treated with radiotherapy alone, and today's intensified therapy does not improve prognosis. More markers are therefore needed to more accurately identify patients with good prognosis or in need of alternative therapy. Here, microRNAs (miRs) 155, 185 and 193b were examined as potential prognostic markers in TSCC/BOTSCC.</p><p>Material and methods: 168 TSCC/BOTSCC patients diagnosed 2000-2013, with known data on HPV-status, CD8(+) tumour infiltrating lymphocytes, tumour staging and survival were examined for expression of miR-155, -185 and -193b using Real-Time PCR. Associations between miR expression and patient and tumour characteristics were analysed using univariate testing and multivariate regression.</p><p>Results: Tumours compared to normal tonsils showed decreased miR-155 and increased miR-193b expression. miR-155 expression was associated with HPV-positivity, low T-stage, high CD8(+) TIL counts and improved survival. miR-185 expression was associated with HPV-negativity and a tendency towards decreased survival, while miR-193b expression was associated with higher T-stage, male gender and lower CD8(+) TIL counts, but not with outcome. Upon Cox regression, miR-185 was the only miR significantly associated with survival. Combining miR-155 and miR-185 to predict outcome in HPV+ patients yielded an area under curve (AUC) of 71%.</p><p>Conclusion: Increased miR-155 expression was found as a positive predictor of survival, with the effect mainly due to its association with high CD8(+) TIL numbers, while miR-185 independently associated with decreased survival. Addition of these miRs to previously validated prognostic biomarkers could improve patient stratification accuracy.</p>
  •  
7.
  • Bersani, Cinzia, et al. (författare)
  • Targeted sequencing of tonsillar and base of tongue cancer and human papillomavirus positive unknown primary of the head and neck reveals prognostic effects of mutated FGFR3
  • 2017
  • Ingår i: OncoTarget. - 1949-2553 .- 1949-2553. ; 8:21, s. 35339-35350
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>BACKGROUND: Human papillomavirus positive (HPV+) tonsillar cancer (TSCC), base of tongue cancer (BOTSCC) and unknown primary cancer of the head and neck (HNCUP) have better outcome than corresponding HPV- cancers. To find predictive markers for response to treatment, and correlations and differences in mutated oncogenes and suppressor genes between HPV+TSCC/BOTSSCC and HPV+ HNCUP and HPV- TSCC/BOTSCC targeted next-generation sequencing was performed of frequently mutated regions in 50 cancer related genes.</p><p>PATIENTS AND METHODS: DNA from 348 TSCC/BOTSCC and 20 HNCUP from patients diagnosed 2000-2011, was sequenced by the Ion Proton sequencing platform using the Ion AmpliSeq Cancer Hotspot Panel v2 to identify frequently mutated regions in 50 cancer related genes. Ion Torrent Variant Caller software was used to call variants.</p><p>RESULTS: 279 HPV+ TSCC/BOTSCC, 46 HPV- TSCC/BOTSCC and 19 HPV+ HNCUP samples qualified for further analysis. Mutations/tumor were fewer in HPV+ TSCC/BOTSCC and HNCUP, compared to HPV- tumors (0.92 vs. 1.32 vs. 1.68). Differences in mutation frequency of TP53 and PIK3CA were found between HPV+ TSCC/BOTSCC and HNCUP and HPV- TSCC/BOTSCC. In HPV+TSCC/BOTSCC presence of FGFR3 mutations correlated to worse prognosis. Other correlations to survival within the groups were not disclosed.</p><p>CONCLUSIONS: In HPV+ TSCC/BOTSCC mutation of PIK3CA was most frequently observed, while TP53 mutations dominated in HPV- TSCC/BOTSCC. In HPV+ TSCC/BOTSCC and HNCUP, mutations/tumor were similar in frequency and fewer compared to that in HPV- TSCC/BOTSCC. Notably, FGFR3 mutations in HPV+ TSCC/BOTSCC indicated worse prognosis.</p>
  •  
8.
  • Dahlgren, Liselotte, et al. (författare)
  • Differences in human papillomavirus type may influence clinical outcome in early stage cervical cancer.
  • 2006
  • Ingår i: Anticancer Research. - 0250-7005 .- 1791-7530. ; 26:2A, s. 829-32
  • Tidskriftsartikel (refereegranskat)abstract
    • <p><strong>BACKGROUND:</strong> The presence of human papillomavirus (HPV), the HPV type and viral load in early stage cervical carcinoma were investigated in order to elucidate whether any of these factors were important for clinical outcome.</p> <p><strong>PATIENTS AND METHODS:</strong> Twelve patients who were disease-free 5 years after diagnosis were matched and compared with 12 patients who died within 2 years. The presence of HPV, HPV type and viral load in their tumours was examined by PCR.</p> <p><strong>RESULTS:</strong> The distribution and load of HPV was similar in the 2 patient groups. HPV-16 was, however, significantly more common in tumours of the surviving patients than in those of patients who died (88.9% and 18.2%, respectively, p = 0.0152).</p> <p><strong>CONCLUSION:</strong> HPV-16 was significantly more common in early stage carcinomas of patients surviving more than 5 years in comparison to early stage carcinomas of patients with a poor prognosis.</p>
  •  
9.
  • Dahlgren, Liselotte, et al. (författare)
  • Human papillomavirus is more common in base of tongue than in mobile tongue cancer and is a favorable prognostic factor in base of tongue cancer patients.
  • 2004
  • Ingår i: International Journal of Cancer. - 0020-7136 .- 1097-0215. ; 112:6, s. 1015-9
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>The frequency of human papilloma virus (HPV) and its influence on clinical outcome was analyzed retrospectively in pre-treatment paraffin embedded biopsies from 110 patients with tongue cancer. The presence of HPV DNA was examined in 85 mobile tongue tumors and 25 base of tongue tumors by a polymerase chain reaction (PCR) with 2 general primer pairs, GP5+/6+ and CPI/IIG. When HPV-DNA was found, HPV-type specific primers and direct sequencing were used for HPV sub-type verification. Twelve of 110 (10.9%) samples were HPV-positive; 9 for HPV-16, 1 for HPV-33, 1 for HPV-35 and 1 could not be analyzed because of shortage of DNA. HPV was significantly more common in base of tongue tumors (10/25, 40.0%) compared to tumors of the mobile tongue (2/85, 2.3%). The influence of HPV on clinical outcome in mobile tongue cancer could not be studied, due to that HPV was present in too few cases. Of the 19 patients with base of tongue cancer that were included in the survival analysis, however, 7 patients with HPV-positive base of tongue cancer had a significantly favorable 5-year survival rate compared to the 12 HPV-negative patients. In conclusion, HPV is significantly more common in base of tongue cancer than in mobile tongue cancer, and has a positive impact on disease-specific survival in patients with base of tongue cancer.</p>
  •  
10.
  • Dahlstrand, Hanna, et al. (författare)
  • Human papillomavirus accounts both for increased incidence and better prognosis in tonsillar cancer.
  • 2008
  • Ingår i: Anticancer Research. - 0250-7005 .- 1791-7530. ; 28:2B, s. 1133-8
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>The aim of this review is to present the current knowledge on the status and significance of human papillomavirus (HPV) in tonsillar cancer. An increase in the incidence of tonsillar cancer has been reported and recent data suggest that this increase is due to an increased proportion of HPV in these tumours. Furthermore, patients with HPV positive cancer have been shown to have a lower risk of relapse and longer survival compared to patients with HPV-negative tonsillar cancer. Tailoring individual treatment in tonsillar cancer may be of importance in order to reduce patient suffering as well as to increase patient survival. Finally, the fact that the presence of HPV-type 16 E6 and E7 mRNA has been ascertained in tonsillar cancer suggests that HPV-16 indeed is an aetiological factor associated with the disease and that preventive vaccination for this patient group should be discussed.</p>
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 39
  • [1]234Nästa
Åtkomst
fritt online (7)
Typ av publikation
tidskriftsartikel (32)
doktorsavhandling (3)
konferensbidrag (2)
forskningsöversikt (2)
Typ av innehåll
refereegranskat (36)
övrigt vetenskapligt (5)
Författare/redaktör
Dalianis, Tina (36)
Lindquist, David, (13)
Munck-Wikland, Eva (13)
Ramqvist, Torbjörn (12)
Näsman, Anders (8)
Grün, Nathalie (7)
visa fler...
Romanitan, Mircea (7)
Tertipis, Nikolaos (6)
Haeggblom, Linnea (6)
Tydén, Tanja, (5)
Bersani, Cinzia (5)
Sivars, Lars (5)
Söderström, Karin, (4)
Zackrisson, Björn, (4)
Rosenblad, Andreas, (4)
Kjellén, Elisabeth (4)
Nilsson, Per (4)
Ye, Weimin (4)
Dalianis, T, (4)
Larsson, Margareta, (4)
Mints, Michael, (4)
Lindholm, Johan, (4)
Ramqvist, Torbjorn (4)
Westerling, Ragnar, (3)
Nevéus, Tryggve, (3)
Stenhammar, Christin ... (3)
Oscarsson, Marie, 19 ... (3)
Ährlund-Richter, And ... (3)
Nasman, Anders (3)
Nilsson, P. (2)
Ekberg, Lars (2)
Reizenstein, Johan, (2)
Soderstrom, K (2)
Friesland, Signe (2)
Kjellen, E (2)
Zackrisson, B (2)
Johansson, Karl-Axel ... (2)
Lewin, Freddi, (2)
Wennberg, Lars (2)
Wennerberg, Johan, (2)
Herthelius, Maria, (2)
Ask, Anders, (2)
Björk-Eriksson, Thom ... (2)
Gustafsson, Britt (2)
Brun, Eva, (2)
Nyman, Jan (2)
Ahrlund-Richter, And ... (2)
Franzen, Lars (2)
Bogdanovic, Gordana (2)
Felldin, Marie, (2)
visa färre...
Lärosäte
Umeå universitet (21)
Uppsala universitet (6)
Karolinska Institutet (4)
Lunds universitet (3)
Linnéuniversitetet (3)
Örebro universitet (2)
visa fler...
Göteborgs universitet (1)
Mälardalens högskola (1)
Linköpings universitet (1)
Sophiahemmet Högskola (1)
visa färre...
Språk
Engelska (38)
Svenska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (39)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy